ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 166 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2019. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $80,000 | +166.7% | 1,348 | +68.1% | 0.00% | – |
Q3 2019 | $30,000 | -21.1% | 802 | -3.0% | 0.00% | – |
Q2 2019 | $38,000 | +15.2% | 827 | 0.0% | 0.00% | – |
Q1 2019 | $33,000 | -31.2% | 827 | -21.0% | 0.00% | – |
Q4 2018 | $48,000 | +336.4% | 1,047 | +349.4% | 0.00% | – |
Q3 2018 | $11,000 | -85.1% | 233 | -77.0% | 0.00% | -100.0% |
Q2 2018 | $74,000 | 0.0% | 1,015 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $74,000 | -26.7% | 1,015 | -33.4% | 0.00% | 0.0% |
Q4 2017 | $101,000 | +27.8% | 1,524 | -2.6% | 0.00% | 0.0% |
Q3 2017 | $79,000 | +61.2% | 1,564 | +49.0% | 0.00% | 0.0% |
Q2 2017 | $49,000 | +58.1% | 1,050 | +18.5% | 0.00% | – |
Q1 2017 | $31,000 | +181.8% | 886 | -1.6% | 0.00% | – |
Q4 2016 | $11,000 | -8.3% | 900 | 0.0% | 0.00% | – |
Q3 2016 | $12,000 | +33.3% | 900 | 0.0% | 0.00% | – |
Q2 2016 | $9,000 | -40.0% | 900 | 0.0% | 0.00% | – |
Q1 2016 | $15,000 | -25.0% | 900 | 0.0% | 0.00% | – |
Q4 2015 | $20,000 | – | 900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |